A Review of the Use of Angiotensin Receptor Blockers for the Prevention of Cardiovascular Events in Patients with Essential Hypertension Without Compelling Indications

Abstract

Spanish

French

OBJECTIVE

To review the role of angiotensin receptor blockers (ARBs) for the prevention of cardiovascular events in patients with essential hypertension without other compelling indications.

DATA SOURCES

Peer-reviewed clinical trials, review articles, and relevant treatment guidelines were identified from MEDLINE and Current Content database (both 1966-November 15, 2012) using the search terms angiotensin receptor blockers (ARBs), azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, hypertension, myocardial infarction, stroke, heart failure, and cardiovascular outcomes. Results were limited to human trials published in English. Citations from articles were also reviewed for additional references.

STUDY SELECTION AND DATA EXTRACTION

The focus was on clinical trials evaluating cardiovascular end points of ARBs used in patients with essential hypertension without compelling indications.

DATA SYNTHESIS

Data supporting the use of ARBs for reducing cardiovascular events in patients with essential hypertension without compelling indications are inconsistent. To date, only candesartan and losartan have shown a significant reduction in cardiovascular morbidity within this sizable subgroup of patients. In the Study on Cognition and Prognosis in the Elderly (SCOPE) trial, candesartan showed a 27.8% reduction in nonfatal stroke versus placebo (95% CI 1.3–47.2; p = 0.04). Moreover, losartan demonstrated a decrease in all cardiovascular events compared to atenolol in the Cardiovascular Morbidity and Mortality in the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study (RR 0.87; 95% CI 0.77–0.98; p = 0.021).

CONCLUSIONS

Data supporting the use of ARBs for reducing cardiovascular events in patients with essential hypertension without compelling indications are limited and inconclusive. More studies are needed before ARBs can be routinely recommended as first-line therapy for hypertension management in patients without other compelling indications.

Get full access to this article

View all access options for this article.

References

1. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. www.nhlbi.nih.gov/guidelines/hypertension/jnc7full.pdf (accessed 2012 Feb 4).

2. NICE clinical guidelines 127. Hypertension: clinical management of primary hypertension in adults. www.nice.org.uk/guidance/CG127 (accessed 2012 Oct 6).

3. The Canadian Hypertension Education Program (CHEP) 2012 recommendations. www.hypertension.ca/chep-recommendations (accessed 2012 Oct 6).

4. Roger

, Go

, Lloyd-Jones

, Heart disease and stroke statistics—2012 update. A report from the American Heart Association statistics committee and stroke statistics committee. Circulation 2012; 125: e2–220.

5. Centers for Disease Control and Prevention. Compressed mortality file: underlying cause of death, 1979 to 2007. Atlanta: Centers for Disease Control and Prevention. http://wonder.cdc.gov/mortSQl.html (accessed 2012 Feb 4).

6. Centers for Disease Control and Prevention. High blood pressure facts. March 21, 2011. www.cdc.gov/bloodpressure/facts.htm (accessed 2012 Feb 4).

7. Staessen

, Wang

, Bianchi

, Birkenhager

. Essential hypertension. Lancet 2003; 361: 1629–41.

8. Kaplan

. Kaplan's clinical hypertension. 9th ed. Philadelphia: Lippincott Williams & Wilkins, 2006.

9. Saseen

, Maclaughlin

. Hypertension. In: DiPiro

, Talbert

, Yee

, et al., eds. Pharmacotherapy: a pathophysiologic approach. 8th ed. New York: McGraw-Hill, 2011: 101–35.

10.

10. Ojima

, Hideki

, Masayuki

, In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther 2011; 336: 801–8.

11.

11. Lip

, Beevers

. More evidence on blocking the renin-angiotensin-aldosterone system in cardiovascular disease and the long-term treatment of hypertension: data from recent clinical trials (CHARM, EUROPA, Val-Heft, HOPE-TOO and SYST-Dur2). J Hum Hypertens 2003; 17: 747–50.

12.

12. Center for Drug Evaluation and Research. Medical review of azilsartan. www.accessdata.fda.gov/drugsatfda_docs/nda/2011/200796Orig1s000 MedR. pdf (accessed 2012 Feb 7).

13.

13. Easthope

, Jarvis

. Candesartan cilexetil: an update of its use in essential hypertension. Drugs 2001; 62: 1253–87.

14.

14. Plosker

. Eprosartan: a review of its use in hypertension. Drugs 2009; 69: 2477–99.

15.

15. Pouleur

. Clinical overview of irbesartan: a new angiotensin II receptor antagonist. Am J Hypertension 1997; 10: 318S–24S.

16.

16. Scott

, McCormack

. Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs 2008; 68: 1239–72.

17.

17. Battershill

, Scott

. Telmisartan: a review of its use in the management of hypertension. Drugs 2006; 66: 55–83.

18.

18. Taylor

, Siragy

, Nesbitt

. Angiotensin receptor blockers: pharmacology, efficacy, and safety. J Clin Hypertension 2011; 13: 677–86.

19.

19. Izzo

, Zion

. Value of angiotensin receptor blocker therapy in diabetes. J Clin Hypertension 2011; 13: 290–5.

20.

20. Chrysant

. Angiotensin II receptor blocker in the treatment of cardiovascular disease continuum. Clin Therapeut 2008; 30 (part 2): 2181–90.

21.

21. Lithell

, Hansson

, Skoog

, for the SCOPE study group. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial J Hypertension 2003; 21: 875–86.

22.

22. Suzuki H, Kanno Y, for the Efficacy of Candesartan on Outcome in Saitama trial (E-COST) group. Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients. Hypertension Res 2005; 28: 307–14.

23.

23. The Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (TRANSCEND) investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet 2008; 372: 1174–83.

24.

24. Dahlof

, Devereux

, Kjeldsen

, Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995–1003.

25.

25. Julius

, Kjeldsen

, Weber

, Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004; 363: 2022–31.

26.

26. Zanchetti

, Julius

, Kjeldsen

, Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens 2006; 24: 2163–8.

27.

27. Kjeidsen

, Stalhammer

, Hasvold

, Bodegard

, Olsson

, Russell

. Effects of losartan vs candesartan in reducing cardiovascular events in primary treatment of hypertension. J Human Hypertens 2010; 24: 263–73.

28.

28. Powers

, Crowley

, McCrory

, Future research needs for comparing angiotensin-converting enzyme inhibitors (ACEs), angiotensin receptor blockers (ARBs), and direct rennin inhibitors (DRIs) in the treatment of hypertension. (Prepared by the Duke Evidence-based Practice Center under contract No. 290-2008-10066-I). AHRQ Publication No. 12-EHC046-EF. Rockville, MD: Agency for Healthcare Research and Quality, March 2012.

29.

29. Law

, Morris

, Wald

. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.

30.

30. Siragy

. Angiotension receptor blockers: how important is selectivity? Am J Hypertension 2002; 15: 1006–14.

31.

31. Product information. Atacand (candesartan cilexetil oral tablets). Wilmington, DE: AstraZeneca LP, April 2012.

32.

32. Product information. Avapro (irbesartan oral tablets). New York: Bristol-Myers Squibb/Sanofi-Synthelabo Partnership, September 2012.

33.

33. Product information. Benicar (olmesartan medoxomil oral tablets). New York: Sankyo Pharma, March 2012.

34.

34. Product information. Cozaar (losartan potassium oral tablets). White-house Station, NJ: Merck Sharp & Dohme Corp., November 2011.

35.

35. Product information. Diovan (valsartan oral tablets). East Hanover, NJ: Novartis Pharmaceuticals Corp., October 2012.

36.

36. Product information. Edarbi (azilsartan medoxomil oral tablets). Deerfield, IL: Takeda Pharmaceuticals America, Inc., July 2012.

37.

37. Product information. Micardis (telmisartan oral tablets). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., September 2012.

38.

38. Product information. Teveten (eprosartan mesylate oral tablets). Bridgewater, NJ: Biovail Pharmaceuticals, Inc., September 2012.

39.

39. Dobrek

, Thor

. Future potential indications for pharmacotherapy using renin-angiotensin-aldosterone system inhibitory agents. Adv Clin Exp Med 2010; 19: 389–98.